Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 10, 2005, Pages 4386-4389

  Boffito, Marta ^a   Pozniak, Anton ^a   Kearney, Brian P ^b   Higgs, Christopher ^a   Mathias, Anita ^b   Zhong, Lijie ^b   Shah, Jaymin ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NELFINAVIR; TENOFOVIR DISOPROXIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; STEADY STATE;

ADENINE; ADULT; AREA UNDER CURVE; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; NELFINAVIR; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 25844472748     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.10.4386-4389.2005     Document Type: Article

References (14)

1. Back, D., G. Gatti, C. Fletcher, R. Garaffo, R. Haubrich, R. Hoetelmans, M. Kurowski, A. Luber, C. Merry, and C. F. Perno. 2002. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 16(Suppl. 1):S5-S37.
2. Birkus, G., M. Hájek, P. Kramata, I. Votruba, A. Holy, and B. Otová. 2002. Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases α, δ, and ε. Antimicrob. Agents Chemother. 46:1610-1613.
3. Boffito, M., D. Back, M. Stainsby-Tron, A. Hill, G. Di Perri, G. Moyle, M. Nelson, J. Tomkins, B. Gazzard, and A. Pozniak. 2005. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir disoproxil fumarate in HIV-1-infected subjects. Br. J. Clin. Pharmacol. 59:38-42.
4. Bristol Meyer Squibb Company. 2004. Reyataz [atazanavir]: summary of product characteristics. Bristol Meyer Squibb Company, Princeton, N.J.
5. Gallant, J. E., S. Staszewski, A. L. Pozniak, E. DeJesus, J. M. Suleiman, M. D. Miller, D. F. Coakley, B. Lu, J. J. Toole, A. K. Cheng, and the 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191-201.
6. Gilead Sciences. 2004. Viread [tenofovir diproxil fumarate]: summary of product characteristics. Gilead Sciences, Foster City, Calif.
7. Kearney, B., J. Flaherty, J. Wolf, J. Sayre, S. Gill, and D. Coakley. 2001. Lack of clinically relevant drug-drug interactions between tenofovir DF and efavirenz, indinavir, lamivudine, and lopinavir/ritonavir in healthy subjects, abstr. 171. Abstr. 8th Eur. Conf. Clin. Aspects Treatment HIV-Infect., Athens, Greece.
8. Kearney, B. P., A. Mittan, J. Sayre, F. Flaherty, I. Zhong, J. J. Toole, and A. K. Cheng. 2003. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir, abstr. A-1617. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
9. Kerr, B., C. Lee, and G. Yuen. 1997. Overview of in vitro and in vivo drug interaction studies of nelfinavir mesylate (NFV), a new protease inhibitor, abstr. 373. Abstr. 4th Conf. Retrovir. Opportunistic Infect., Washington, D.C.
10. Kruse, G., S. Esser, H. Stocker, A. Breske, A. Koerber, M. Kopperman, H. Wiehler, B. Ross, C. Mocklinghoff, A. Hill, M. Becker, and M. Kurowski. 2005. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients. Antivir. Ther. 10:349-355.
11. Poirier, J., J. Meynard, J. Guiard-Schmid, P. Girard, W. Rozenbaum, and P. Jaillon. 2002. Lack of alteration of lopinavir and ritonavir through plasma concentrations in HIV-experienced patients treated with kaletra and tenofovir DF, abstr. H-1715. Abstr. 42nd Int. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
12. Roche. 2004. Viracept [nelfinavir]: summary of product characteristics. Roche, Welwyn Garden City, Hertfordshire, United Kingdom.
13. Squires, K., A. L. Pozniak, G. Pierone, C. R. Steinhart, Jr., D. Berger, N. C. Belles, S. L. Becker, M. Wulfsohn, M. D. Miller, J. J. Toole, D. F. Coakley, A. Cheng, and the Study 907 Team. 2003. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann. Intern. Med. 139:313-320.
14. Zong, J., G. Chttick, M. R. Blum, D. Hill, J. Begley, N. Adda, J. Shah, and B. P. Kearney. 2004. Pharmacokinetic assessment of tenofovir DF (TDF) and ritonavir (RTV)-boosted saquinavir (SQV/r) in healthy subjects, abstr. A-444. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.